The CYP3A4*3 allele: is it really rare?

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Chemistry

• Publication date

  2001-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/clinchem/47.6.1104PMID 11375299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing

  2004cited by this paper
• Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

  2002cited by this paper
• More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

  2000cited by this paper
• Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa.

  2000cited by this paper
• CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

  2000cited by this paper
• CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism

  2000cited by this paper
• CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.

  2000cited by this paper
• Cytochrome P450 3A

  1999cited by this paper
• Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4

  1999cited by this paper
• Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

  1999cited by this paper
• Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4

  1999cited by this paper
• Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.

  1999cited by this paper
• Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

  1998cited by this paper
• Association of CYP3A4 genotype with treatment-related leukemia.

  1998cited by this paper
• Elevated Plasma Levels of Homocysteine inParkinson’s Disease

  1998cited by this paper
• Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

  1997cited by this paper
• Sulfate and cysteine levels in the plasma of patients with Parkinson's disease.

  1995cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

  1994cited by this paper
• The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature

  1991cited by this paper
• Genotype or phenotype: the definition of a pharmacogenetic polymorphism.

  1991cited by this paper
• Assessment of Parkinson's Disease

  1984cited by this paper

• New Insights into Prostate Cancer Susceptibility in European Caucasians: A Systematic Review and Meta-Analysis of CYP3A4 Pharmacogene

  2025cites this paper
• Drug Metabolizing Enzymes: An Exclusive Guide into Latest Research in Pharmaco-genetic Dynamics in Arab Countries.

  2024cites this paper
• Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients.

  2022cites this paper
• Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study

  2021influential citation
• Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug

  2021cites this paper
• Do and genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

  2020cites this paper
• Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)

  2020cites this paper
• Interindividual Variability in the Cytochrome P450 3A4 Drug Metabolizing Enzyme: Effect of the CYP3A4*1G Genetic Variant

  2019cites this paper
• Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro

  2019cites this paper
• Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

  2016cites this paper
• Cytochrome and sulfotransferase gene variation in north African populations.

  2016cites this paper
• Interindividual Variability in the Cytochrome P 450 3 A 4 Drug Metabolizing Enzyme : Effect of the CYP 3 A 4 * 1 G Genetic Variant Chairperson :

  2016cites this paper
• بررسی ارتباط بین پلی مورفیسم در ژن CYP3A5 با سرطان مثانه

  2015cites this paper
• Pharmacogenetics and Antipsychotic Treatment Response/ Фармакогенетски Тестирања И Одговор Кон Третман Со Антипсихотоци

  2015cites this paper
• Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

  2015cites this paper
• Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia

  2015cites this paper
• Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.

  2014cites this paper
• Interindividual Variability in the Cytochrome P450 3A4 Drug Metabolizing Enzyme: Effect of the CYP3A4*1G Genetic Variant

  2014cites this paper
• Genotypic and expression analysis of CYP3A4 and CYP3A5 in patients with chronic myeloid leukaemia

  2013influential citation
• Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

  2013cites this paper
• Characterization of single nucleotide polymorphisms of cytochrome p450 in an Australian deceased sample.

  2012cites this paper
• Prolonged excretion of 7-aminoclonazepam in urine after repeated ingestion of clonazepam: a case report.

  2012cites this paper
• Personalised Medicine in New Zealand: A new approach to healthcare delivery

  2011cites this paper
• Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects

  2011cites this paper
• Tumor and patient profiling to predict clinical outcome in patients with colorectal cancer

  2011cites this paper
• Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients

  2010cites this paper
• Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.

  2010cites this paper
• Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

  2010cites this paper
• Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An

  2010cites this paper
• The screening for single nucleotide polymorphisms of CYP3A4 in chronic myelogenous leukemia patients receiving imatinib

  2009cites this paper
• Studies on CYP 1 A 1 , CYP 1 B 1 and CYP 3 A 4 gene polymorphisms in breast cancer patients

  2009cites this paper
• Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

  2009cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• QUE COMO UNO DE LOS REQUISITOS PARA OBTENER EL GRADO DE

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009influential citation
• Factors Affecting Pharmacokinetic Variability of Imatinib Mesylate (Gleevec, STI-571)

  2008cites this paper
• The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

  2008cites this paper
• Clinical pharmacogenetics and potential application in personalized medicine.

  2008cites this paper
• UNIVERSITATIS UPSALIENSIS UPPSALA 2008 Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 335 Pharmacogenetics and Antipsychotic Treatment in Schizophrenia with Special Focus on Adverse Drug Reactions

  2008influential citation
• Pharmacodynamics of Carbamazepine‐mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin

  2008cites this paper
• THE PHARMACOLOGY OF OXYCODONE, Studies In Vitro, In Vivo and in Humans

  2008cites this paper
• Role of CYP3A5 in Abnormal Clearance of Methadone

  2008cites this paper
• ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety

  2008cites this paper
• Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers

  2007cites this paper
• Influence of ketoconazole on the fecal and urinary disposition of docetaxel

  2007cites this paper
• Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

  2007cites this paper
• Pharmacokinetic Optimization of Docetaxel Dosing

  2006cites this paper
• A Roadmap to Individualized Irinotecan Dosing

  2006cites this paper
• Cytochrome P450 and anticancer drugs.

  2006cites this paper
• Role of pharmacogenetics in irinotecan therapy.

  2006cites this paper
• Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.

  2006cites this paper
• Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

  2006cites this paper
• Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

  2005cites this paper
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

  2005cites this paper
• An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore

  2005influential citation
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

  2005cites this paper
• Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences.

  2005cites this paper
• Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

  2005cites this paper
• EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS

  2005influential citation
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes

  2005cites this paper
• Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.

  2004cites this paper
• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  2004cites this paper
• Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes

  2004cites this paper
• Implications of Cytochrome P450 Genetic Polymorphisms on the Toxicity of Antitumor Agents

  2004cites this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cites this paper
• Recent advances in pharmacogenetic approaches to anticancer drug development

  2004cites this paper
• In vitro characterization of the human biotransformation of marine derived anti-cancer drugs

  2004cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cites this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cites this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cites this paper
• Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.

  2002cites this paper
• Therapy with Antidepressants: Pharmacogenetic Aspects

  2002cites this paper
• Developmental aspects of midazolam metabolism

  2001cites this paper